Karyopharm Therapeutics Inc. Peo Actually Paid Comp Amt
Karyopharm Therapeutics Inc. (KPTI) reported Peo Actually Paid Comp Amt of $2.12 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-13.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:PeoActuallyPaidCompAmt · last filed 2026-04-13
| Period end | Peo Actually Paid Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.12M DEF 14A · filed 2026-04-13 |
| 2024-12-31 | $1.65M DEF 14A · filed 2026-04-13 |
| 2023-12-31 | $35.74K DEF 14A · filed 2026-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |